Next Article in Journal
A Unique Case of Durable Complete Remission after Salvage with Azacitidine and DLI for High Risk FLT-3 Positive Acute Myeloid Leukemia, Following Relapse 18 Months Post Allogeneic Stem Cell Transplant
Previous Article in Journal
Use of Catridecacog in a Patient with Severe Factor XIII Deficiency Undergoing Surgery
 
 
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Patterns of Prescribing Hydroxyurea for Sickle Cell Disease Patients from a Central Hospital, Saudi Arabia

Department of Adult Hematology Oncology, King Saud Medical City, AlShemisy Area, P.O. Box 366254, Riyadh 11393, Saudi Arabia
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2019, 11(1), 7860; https://doi.org/10.4081/hr.2019.7860
Submission received: 3 September 2018 / Revised: 1 December 2018 / Accepted: 7 December 2018 / Published: 19 February 2019

Abstract

Sickle cell disease (SCD) is a group of inherited disorders of hemoglobin synthesis. It is prevalent in different parts of the world, including the Kingdom of Saudi Arabia. The disease is associated with multiple acute and chronic life-threatening complications. Hydroxyurea (HU) is an effective preventive medication; its use has resulted in decreased morbidity and mortality. However, practice variability, including underutilization of HU, has been reported. No local publication has addressed this issue. The aim of this work is to consider the pattern of HU prescription for SCD patients. This is a retrospective study included patients seen in the outpatient clinics in a central hospital. Cases of medications unavailability or patient refusal to take the drug were not included. A total of 152 patients were included, of them 118 were prescribed HU and 34 were not. In 133 (87.5%) patients, the physician’s decision was appropriate. Inappropriate decisions including both under prescription and, to much lesser extent, over utilization had been demonstrated in 19 (12.5%) cases. Impact of raising the healthcare providers’ awareness and improving compliance with the updated SCD management recommendations and guidelines deserve further studying. In our local experience, although the majority of HU prescriptions were appropriate, both under prescription and to a lesser extent, overutilization was demonstrated.
Keywords: SCD; HU; over- and under prescription SCD; HU; over- and under prescription

Share and Cite

MDPI and ACS Style

Elghazaly, A.A.; Aljatham, A.A.; Khan, A.M.; Elneil, R.M.; Jafar, S.Z.S.; Elwishy, S.A.; Ahmed, O.E.; Bughnah, A.M.; Ibrahim, M.H. Patterns of Prescribing Hydroxyurea for Sickle Cell Disease Patients from a Central Hospital, Saudi Arabia. Hematol. Rep. 2019, 11, 7860. https://doi.org/10.4081/hr.2019.7860

AMA Style

Elghazaly AA, Aljatham AA, Khan AM, Elneil RM, Jafar SZS, Elwishy SA, Ahmed OE, Bughnah AM, Ibrahim MH. Patterns of Prescribing Hydroxyurea for Sickle Cell Disease Patients from a Central Hospital, Saudi Arabia. Hematology Reports. 2019; 11(1):7860. https://doi.org/10.4081/hr.2019.7860

Chicago/Turabian Style

Elghazaly, Assem A., Adel A. Aljatham, Abdulaziz M. Khan, Rasha M. Elneil, S. Zubair S. Jafar, Salah A. Elwishy, Omsalma E. Ahmed, Aamer M. Bughnah, and Mamoun H. Ibrahim. 2019. "Patterns of Prescribing Hydroxyurea for Sickle Cell Disease Patients from a Central Hospital, Saudi Arabia" Hematology Reports 11, no. 1: 7860. https://doi.org/10.4081/hr.2019.7860

Article Metrics

Back to TopTop